Mod­er­na said its cy­tomegalovirus vac­cine failed a Phase 3 study and it will end fur­ther de­vel­op­ment of the shot for most pa­tients. The com­pa­ny said Wednes­day that the ef­fi­ca­cy of the vac­cine, called mR­NA-1647, ranged from 6% to 23% de­pend­ing on case de­f­i­n­i­tion...